欢迎访问《现代生物医学进展》编辑部！

目的：探讨血清长链非编码RNA MALAT-1检测在卵巢癌患者中的诊断作用。方法：收集187 例在我院行卵巢肿瘤切除术患者术前血清。应用实时定量PCR 检测血清中MALAT-1 mRNA的表达。MALAT-1 mRNA 的拷贝数使用绝对定量（标准曲线）计算。MALAT-1 的诊断价值采用ROC-AUC曲线和logistic回归分析并与血清CA125 进行比较。结果：1本研究有效样本比例为 88.77%（166/187）。卵巢良性肿瘤和恶性肿瘤比例分别为62.05%（103/166）和37.95%（63/166）。卵巢恶性肿瘤患者MALAT-1 明显高于良性肿瘤患者（p<0.001）。经ROC 曲线分析，血清CA125 和MALAT-1 曲线下面积分别为0.726 和0.844，且血清 MALAT-1 的诊断价值明显优于血清CA125（p=0.023）。经logistic 回归分析，应用血清MALAT-1 和CA125 的预测准确性分别为 78.92%和68.07%，应用血清MALAT-1 可提高预测准确性10.85%。进一步的分析得出，取血清MALAT-1 截断点为36.5 时，其预测的敏感性和特异性分别高达84.1%和67.0%。结论：血清长链非编码RNA MALAT-1 检测对卵巢肿瘤的性质具有良好的预测作用，可作为卵巢癌早期诊断的分子标志物。本研究结果需大样本前瞻性的研究进一步验证。

英文摘要:

Objective:To evaluate the diagnostic power of serum-based long non-coding RNA MALAT-1 detection to ovarian cancer.Methods:Serum was collected from187 women before ovarian tumor resection. The expression of serum MALAT-1 mRNA was determined by quantitative real time polymerase chain reaction (qRT-PCR). The MALAT-1 copies were calculated using a standard curve. The ability of the MALAT-1 to predict the tumor outcome was assessed with an AUC-ROC analysis and logistic regression. Then, the diagnostic power of serum MALAT-1 was compared with the serum CA125 levels.Results:The informative specimen rate was 88.77% (166/187). The rates of benign tumor and ovarian cancer were 62.05%(103/166) and 37.95%（63/166）, respectively. The copies of serum MALAT-1 were significantly higher in patients with ovarian cancers than in those with benign ones (P<0.001). The ROC curve analysis demonstrated that the area under the ROC curve (AUC) of serumCA125 and MALAT-1 was 0.726 and 0.844, respectively. Further analysis revealed that serumMALAT-1 was much better than CA125 to diagnosing ovarian cancer (p=0.023). The logistic regression analysis demonstrated that the predictive accuracy was increased by 10.85%, by using serum MALAT-1 (78.92%), compared to CA125 (68.07%). Further analysis showed that its sensitivity and specificity were as high as 84.1% and 67.0%respectively when taking 36.5 as the cutoff site of serumMALAT-1.Conclusion:Serum MALAt-1 was found to be a good predictor of ovarian cancer before surgery and it can be a useful serum-based biomarker to diagnose ovarian cancer. Further large-scale prospective studies are needed to confirm our findings.

View Full Text View/Add Comment Download reader